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Abstract. Cranberry flavonoids (flavonols and flavan-3-ols),
in addition to their antioxidant properties, have been shown
to possess potential in vitro activity against several cancers.
However, the difficulty of isolating cranberry compounds
has largely limited anticancer research to crude fractions
without well-defined compound composition. In this study,
individual cranberry flavonoids were isolated to the highest
purity achieved so far using gravity and high performance
column chromatography and LC-MS characterization. MTS
assay indicated differential cell viability reduction of SKOV-3
and OVCAR-8 ovarian cancer cells treated with individual
cranberry flavonoids. Treatment with quercetin aglycone and
PAC DP-9, which exhibited the strongest activity, induced
apoptosis, led to caspase-3 activation and PARP deactivation,
and increased sensitivity to cisplatin. Furthermore, immunofluorescence microscopy and western blot study revealed reduced
expression and activation of epidermal growth factor receptor
(EGFR) in PAC DP-9 treated SKOV-3 cells. In addition,
quercetin aglycone and PAC DP-9 deactivated MAPK-ERK
pathway, induced downregulation of cyclin D1, DNA-PK,
phospho-histone H3 and upregulation of p21, and arrested cell
cycle progression. Overall, this study demonstrates promising
in vitro cytotoxic and anti-proliferative properties of two
newly characterized cranberry flavonoids, quercetin aglycone
and PAC DP-9, against ovarian cancer cells.
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Introduction
Epithelial ovarian cancer (EOC) is an asymptotic lethal disease
that is frequently diagnosed at late stages in women (1). Initial
responsiveness to chemotherapy and surgery is often thwarted
by inherent or acquired resistance, resulting in early recurrence
and premature death (2). Approximately 22,000 women will
be diagnosed with EOC this year in the US alone, and more
than 14,000 will succumb to their disease (3). Because firstline platinum-taxane and second-line dox-topotecan therapies
often fail, third-line chemotherapy options are urgently needed.
American cranberry (Vaccinium macrocarpon) has
received attention in our laboratories and elsewhere because
of the potential for cranberry A-type proanthocyanidins
(PACs) and flavonols to treat upper urinary tract infections and
cancer (4-6). However, the isolation of pure PACs and flavonol
constituents has remained an unmet challenge that frequently
impedes broad-spectrum screening for biological activity.
Semi-pure cranberry PACs have consistently exhibited potent
anti-proliferative activity against various cancer cells in vitro
(6-8). We had previously developed an iterative but efficient
HPLC and mass spectrometry-based approach to generate
high-purity polymeric PAC fractions from cranberries (9).
Purified PACs have exhibited cytotoxic effects against a panel
of gynecologic cancer and neuroblastoma cells in our laboratories (9-11). PACs exerted these cytotoxic effects via cell
cycle arrest, production of lethal levels of intracellular reactive
oxygen species (ROS), and induction of pro-apoptotic signal
transductions at low microgram concentrations (10,11). Further
optimization of the purification and a detailed investigation of
the mechanism of anti-proliferative action have been pursued
in our laboratories since purified PACs became accessible.
In this study, we further elaborate analytical methodology
to isolate and purify individual flavonols and PACs of cranberry for broad-spectrum biological activity screening studies.
We also describe the two most active leads, PAC DP-9 and
quercetin aglycone, in SKOV-3 and OVCAR-8 ovarian cancer
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cells, and we characterize their anti-proliferative efficacy and
mechanism of cell cycle arrest, induction of apoptotic activities, and inhibition of oncogenes and DNA repair machinery.
The multifaceted anti-proliferative properties exerted by these
two cranberry flavonoids highlight their potential for treatment of ovarian cancer.
Materials and methods
Plant material. Cranberry fruits of cultivar ‘Stevens’ were
harvested from the Philip E. Marucci Center for Blueberry and
Cranberry Research and Extension and kept frozen at -20˚C
before use.
Reagents and LC-MS instrumentation. All solvents were
purchased from EMD Millipore (Billercia, MA, USA).
Sephadex ® LH-20 was obtained from GE Healthcare
Bio-Science (Piscataway, NJ, USA), and BakerBound® Diol
was obtained from Avantor Performance Materials (Center
Valley, PA, USA). LC-MS spectra were obtained with a
Dionex UltiMate ® 3000 LC system (Thermal Scientific,
Sunnyvale, CA, USA) including the UltiMate 3000 RS Pump,
UltiMate 3000 RS Autosampler, UltiMate 3000 RS Column
Compartment and UltiMate 3000 RS Diode Array Detector
coupled with Applied Biosystems API 3000TM triple quad
LC-MS/MS mass spectrometer (AB SCIEX, Framingham,
MA, USA). Previously described HPLC methods for flavonol
and PAC identification (12,13) were modified slightly for
LC-MS analysis. Structure and purity of flavonols and PACs
were determined by HPLC-PDA/Fluorescence and/or LC-MS.
Extraction and isolation of individual cranberry flavonols
and PACs. Crude flavonoids were extracted and further separated in a Sephadex LH-20 column as previously described
(14). Individual cranberry flavonols were isolated using a
semi-preparative HPLC system as described previously (14).
Individual PACs were isolated with a regular Diol gravity
column chromatography as previously reported (9). Eight
flavonols were isolated and characterized as myricetin3-galactoside, quercetin-3-galactoside, quercetin-3-glucoside,
quercetin-3-xylopyranoside, quercetin-3-arabinopyranosdie,
quercetin-3-arabinofuranoside, quercetin-3-rhamnopyranoside
and quercetin aglycone. Eleven cranberry A-type PACs from
dimer to polymer 12 (named as PAC DP-2 to PAC DP-12) were
isolated and characterized. Purity of all isolated cranberry flavonoids was > 95% (w/w) based on HPLC and LC-MS analysis.
Cell lines and cell culture. SKOV-3 and OVCAR-8 cells
(ovarian epithelial adenocarcinoma) were purchased
from ATCC (Manassas, VA, USA). Cells were cultured
with Dulbecco's modified Eagle's medium (DMEM, Life
Technologies, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum (Life Technologies), 100 µg/ml streptomycin and 100 µg/ml penicillin (Life Technologies) in an
incubator at 37˚C, 5% CO2 and 95% humidity. For all assays,
cells were allowed to attach for 24 h prior to treatment.
Cell viability assay. Cells (5,000/well) were seeded in 96-well
flat bottom plates (USA Scientific, Orlando, FL, USA) and
treated with various concentrations of flavonoids for 72 h.
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Cell viability was determined by CellTiter 96® Aqueous One
Solution assay (Promega, Madison, WI, USA) following the
manufacturer's protocol. Experiments were performed in triplicate; data are expressed as mean of triplicate measurements
(mean ± SD) in percentage of untreated cells (100%). SPSS
Statistics 19 (IBM Corp., Armonk, NY, USA) was used to
perform ANOVA with linear regression between cell viability
and compound concentration, calculate IC50 value of each
cranberry flavonoid, and conduct Student's t-tests and calculate
p-values based on mean cell viability for each treatment.
DNA fragmentation analysis. DNA fragmentation as a hallmark
of apoptosis was studied using the Roche In Situ Cell Death
Detection kit (Branford, CT, USA) (TUNEL assay). SKOV-3
and OVCAR-8 cells (2x10 4/well) were seeded in Lab-Tek
8-well chamber glass slides (Nalge Nunc., Naperville, IL,
USA) and treated with 50 µg/ml PAC DP-9, 25 µg/ml quercetin
aglycone, or DMSO vehicle control for 12 h. Cells were fixed
with 10% neutral buffered formalin, and stained according to
the manufacturer's protocol. Slides were then cover-slipped
with Vectashield mounting medium with DAPI (Vector
Laboratories, Burlingame, CA, USA). Images were acquired
on a Nikon E800 upright microscope (Nikon Instruments, Inc.,
Melville, NY, USA) using SPOT Advanced Software (SPOT
Imaging Solutions, Sterling Heights, MA, USA).
Western blot analysis. Cells (3x106/dish) were seeded into
100-mm 2 tissue culture dishes and treated with individual
cranberry flavonoids. Cells were then lysed with cell lysis
buffer (Cell Signaling Technology, Inc., Danvers, MA, USA)
supplemented with 5 µl/ml phenylmethylsulfonyl fluoride
(Sigma-Aldrich, St. Louis, MO, USA). Protein concentrations
of cell lysates were determined with Pierce BCA protein assay
kit (Pierce Technology, Rockford, IL, USA). Gel electrophoresis
was performed in NuPAGE Gel system (Life Technologies)
according to the manufacturer's instructions. Separated proteins
were transferred onto a nitrocellulose membrane, which was
then blocked with 5% non-fat milk in PBS-Tween buffer and
probed against various primary antibodies (cleaved caspase-3
no. 9664, cleaved PARP no. 5625, EGFR no. 4267, phosphoEGFR no. 3777, phospho-c-Raf no. 9427, phospho-ERK1/2
no. 4370, phospho-p53 no. 9286, p18 INK4C no. 2896, p21 Waf1/
Cip1 no. 2947, p27 Kip1 no. 3686, CDK2 no. 2546, cyclin D1
no. 2926, cyclin D3 no. 2936, β -actin no. 8457, β -tubulin
no. 2128; Cell Signaling Technology). Protein bands were
visualized using horseradish peroxidase conjugated anti-rabbit
or anti-mouse secondary antibody (Cell Signaling Technology)
and Pierce ECL Western Blotting Substrate, and documented by
Bio-Rad Gel Doc system (Bio-Rad, Hercules, CA, USA).
Immunofluorescence microscopy analysis. SKOV-3 and
OVCAR-8 cells (2x104/well) were seeded in Lab-Tek 8-well
chamber slides and treated with individual cranberry flavonoids
overnight for 12 h. Cells were fixed with 10% neutral buffered
formalin, washed 3 times with PBS-Tween 0.1% and blocked
with 5% horse serum (Vector Laboratories) in PBS-Tween for
30 min. Blocked cells were incubated with various primary
antibodies (EGFR no. 4267, p21 Waf1/Cip1 no. 2947, phosphoERK1/2 no. 4370, DNA-PK no. 4602, Cell Signaling Technology;
and MEK no. sc-166197, phospho-histone H3 no. sc-12927,
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Figure 1. Structures of cranberry flavonoids quercetin aglycone and PAC DP-9. (A) HPLC chromatograph of quercetin aglycone; (B) HPLC chromatograph of
PAC DP-9; (C) MS spectrum of quercetin aglycone (m/z=301); (D) Structures of quercetin algycone and PAC DP-9.

cyclin D1 no. sc-246, Santa Cruz Biotechnology, Dallas, TX,
USA) at 4˚C overnight. Probed proteins were visualized with
DyLight 488/594 (Thermo Scientific, Waltham, MA, USA) or
Alexa Fluor® 594 (Cell Signaling Technology) secondary antibodies, and nuclei were stained with Vectorshield® mounting
medium with DAPI (Vector Laboratories). Images were
acquired on Olympus FSX100® (Olympus America Inc., Center
Valley, PA, USA; for EGFR) or Nikon E800 upright (for other
proteins) microscope system.
Co-immunoprecipitation analysis. SKOV-3 and OVCAR-8
cells were cultured in 100 mm 2 tissue culture dishes to
80% confluency. Cells were lysed and protein concentration
was quantified as described earlier. Lysate containing 500 µg
protein was incubated with target antibody or control IgG antibody (Cell Signaling Technology) for 4 h with rotation at 4˚C.
Protein G sepharose (75 µl) (50% slurry, GE Healthcare Life
Sciences) was added to the lysate and incubated at 4˚C overnight. After incubation, beads were washed with 500 µl lysis
buffer 3 times and re-suspended in 40 µl Laemmli buffer (2X,
Bio-Rad), vortexed, and heated to 95˚C for 5 min. Suspension
was centrifuged to collect supernatant for western blot analysis.
Cell cycle analysis. SKOV-3 and OVCAR-8 cells (3x105/well)
were seeded in 6-well plates and treated with a series of concentrations of individual cranberry flavonoids (0-100 µg/ml,
24-48 h). After trypsinization, cells were collected and fixed
in ice-cold 70% ethanol and stained with solution containing
propidium iodide (Sigma-Aldrich; 0.1 mg/ml), sodium citrate
(Sigma-Aldrich; 2 mg/ml) and Triton X-100 (Sigma-Aldrich;

1 µl/ml). Cell counting data were acquired in an Accuri® C6
Flow Cytometer (BD Biosciences, San Jose, CA, USA) and
analyzed with ModFit LT software (Verity Software House,
Inc., Topsham, ME, USA).
Results
Individual cranberry flavonoids display differential cytotoxicity against ovarian cancer cell lines. Individual cranberry
flavonols and PACs exhibited different levels of cytotoxicity
against SKOV-3 and OVCAR-8 cell-lines (Fig. 2). Quercetin-3xylopyranoside did not show cytotoxicity against SKOV-3 and
OVCAR-8 cells, while myricetin-3-galactoside and quercetin3-arabinopyranoside were cytotoxic to OVCAR-8 cells (IC50,
130 and 212 µg/ml) but non-toxic to SKOV-3 cells at treatment
concentrations. Compared to quercetin glycosides, quercetin
aglycone exhibited higher cytotoxicity against the two cancer
cell lines (IC50, 83 and 61 µg/ml for SKOV-3 and OVCAR-8
cells, respectively).
Cranberry PAC DP-3, DP-7, and DP-10 exhibited less cytotoxicity against both SKOV-3 and OVCAR-8 cells than other
PACs. PAC DP-5 and DP-12 were more effective against
SKOV-3 cells (IC50, 126 µg/ml and 162 µg/ml for DP-5 and
DP-12, respectively) than OVCAR-8 cells. Compared to other
cytotoxic PAC molecules, PAC DP-9 exhibited the highest
activity against SKOV-3 cells (IC50, 82 µg/ml) and relatively
high cytotoxicity against OVCAR-8 cells (IC50, 138 µg/ml).
Based on these results, quercetin aglycone and PAC DP-9
(Fig. 1) were selected as lead candidates for our studies in
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Figure 2. Cytotoxicity of individual cranberry flavonols and PACs in SKOV-3 and OVCAR-8 ovarian cancer cells. Cytotoxicity was determined by MTS
cell viability assay; cells were treated with DMSO vehicle or different concentrations of cranberry flavonoids (25-200 µg/ml) for 72 h. Experiments were
performed in triplicate; data are expressed as mean ± SD in percent of cell viability of untreated cells (100%). M-Gal, myricetin-3-galactoside; Q-Gal,
quercetin-3-galactoside; Q-Glu, quercetin-3-glucoside; Q-A-P, quercetin-3-arabinopyranoside; Q-A-F, quercetin-3-arabinofuranoside; Q-Xylo, quercetin3-xylopyranoside; Q-Rhamno, quercetin-3-rhamnopyranoside;Q-Aglycone, quercetin aglycone.
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Table I. Correlation coefficient (r), p-value and IC50 value of individual cranberry PACs and flavonols against SKOV-3 and
OVCAR-8 cells.a
SKOV-3
OVCAR-8
	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Compound
Correlation coefficient
p-value
IC50 (µg/ml) Correlation coefficient
p-value
IC50 (µg/ml)
DP-2
DP-3
DP-4
DP-5
DP-6
DP-7
DP-8
DP-9
DP-10
DP-11
DP-12
M-Gal
Q-Gal
Q-Glu
Q-A-P
Q-A-F
Q-Xylo
Q-Rhamno
Q-Aglycone

-0.917
-0.804
-0.923
-0.983
-0.929
-0.821
-0.944
-0.939
-0.494
-0.966
-0.824
0.331
-0.833
-0.899
-0.665
-0.791
0.095
-0.879
-0.982

0.0000263
0.00163
0.0000185
1.15x10-8
0.0000129
0.00106
0.00000397
0.00000584
0.103
3.53x10-7
0.000978
0.293
0.000757
0.0000684
0.0182
0.00217
0.77
0.000167
1.45x10-8

194.8
210.8
200.0
126.3
201.1
288.7
137.9
81.9
ND
165.9
162.6
ND
164.8
160.6
410.2
173.5
ND
207.4
83.2

-0.919
-0.513
-0.936
-0.738
-0.9
-0.736
-0.945
-0.923
-0.565
-0.931
-0.791
-0.78
-0.896
-0.929
-0.777
-0.908
-0.266
-0.945
-0.966

0.0000239
0.0882
0.00000741
0.00616
0.0000674
0.00631
0.00000356
0.0000189
0.0558
0.0000107
0.00216
0.00275
0.000082
0.000013
0.00293
0.0000435
0.404
0.00000369
3.48x10-7

143.1
ND
164.1
209.9
152.6
211.2
125.7
137.8
ND
146.9
248.5
130.7
132.7
160.6
212.7
171.2
ND
163.4
61.1

Linear regression was conducted for each cranberry flavonoid between cell viability and compound concentration (untransformed and logarithmtransformed). IC50 value was calculated based on best-fit regression model (r closer to -1). ND, not determined; M-Gal, myricetin-3-galactoside;
Q-Gal, quercetin-3-galactoside; Q-Glu, quercetin-3-glucoside; Q-A-P, quercetin-3-arabinopyranoside; Q-A-F, quercetin-3-arabinofuranoside;
Q-Xylo, quercetin-3-xylopyranoside; Q-Rhamno, quercetin-3-rhamnopyranoside; Q-Aglycone, quercetin aglycone.

a

SKOV-3 and OVCAR-8 cells. Cytotoxicity values for individual flavonoids and statistical analysis including p-values
and correlation coefficients are provided in Table I.
Quercetin aglycone and PAC DP-9 induced apoptosis and
increased cisplatin sensitivity in SKOV-3 and OVCAR-8 cells.
To examine whether apoptosis was induced in ovarian cancer
cells upon treatment with cranberry flavonoids, western blot
and DNA fragmentation analysis (TUNEL assay) were carried.
As shown in Fig. 3A, quercetin aglycone induced caspase-3
activation in both SKOV-3 and OVCAR-8 cells, and PAC DP-9
led to caspase-3 and cleaved-PARP expression specifically in
SKOV-3 cells.
TUNEL assay was performed to detect apoptosis-induced
DNA fragmentation. Quercetin aglycone and PAC DP-9
treated cells showed apoptosis-induced DNA fragmentation,
which was detected in both SKOV-3 and OVCAR-8 cells after
12 h of treatment (Fig. 3B). Both western blot and DNA fragmentation analysis confirmed apoptosis induction in ovarian
cancer cells exposed to these two cranberry flavonoids.
To investigate whether quercetin aglycone and PAC DP-9
could sensitize ovarian cancer cells to cisplatin, cells were
pretreated with subtoxic concentrations of quercetin aglycone
or PAC DP-9 for 6 h, exposed to cisplatin overnight for 12 h,

and cell viability was analyzed. As shown in Fig. 3C, while
subtoxic concentrations of quercetin aglycone or PAC DP-9
alone did not reduce SKOV-3 and OVCAR-8 cell viability,
their pretreatment significantly reduced viability of cisplatintreated SKOV-3 and OVCAR-8 cells, with quercetin aglycone
acting more strongly than PAC DP-9. Thus, quercetin aglycone
and PAC DP-9 at low concentrations sensitize the response of
cisplatin-resistant ovarian cancer cells to cisplatin, resulting in
enhanced cytotoxicity.
PAC DP-9 downregulated expression and activation of
epidermal growth factor receptor (EGFR) in SKOV-3 cells
and induced EGFR nuclear translocation. Elevated EGFR
expression results in poor prognosis in lung, breast and
ovarian cancer (15). EGFR expression in quercetin aglycone
or PAC DP-9 treated ovarian cancer cells was analyzed by
immunoblotting and immunofluorescence microscopy. To
eliminate the effect of serum growth factors on cellular EGFR
regulation, ovarian cancer cells were serum-deprived for 4 h
prior to treatment, and low concentrations (5-40 µg/ml) of
cranberry flavonoids were applied with serum-free medium to
avoid cell toxicity. After 12 h of treatment, quercetin aglycone
did not affect phosphorylated-EGFR levels in either SKOV-3
or OVCAR-8 cells, but PAC DP-9 induced a dose-dependent
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Figure 3. Induction of apoptosis (A and B) and sensitization to cisplatin (C) by quercetin aglycone and PAC DP-9 in SKOV-3 and OVCAR-8 cells. (A) Expression
of cleaved caspase-3 and cleaved PARP after treatment with PAC DP-9 and quercetin aglycone. Ovarian cancer cells were treated with PAC DP-9 or quercetin
aglycone (80 µg/ml) for 0-24 h. Actin or tubulin were probed as internal loading controls; (B) TUNEL assay in PAC DP-9 and quercetin aglycone (Q-A)-treated
SKOV-3 and OVCAR-8 cells. Cells were treated with PAC DP-9 (50 µg/ml), quercetin aglycone (25 µg/ml) or DMSO vehicle for 12 h. DNA strand breaks due
to apoptosis were detected and labelled by fluorescein-labelled nucleotides (green). (C) Cell viability of cranberry flavonoid and cisplatin-treated SKOV-3 and
OVCAR-8 cells. Cells were pre-treated with either DMSO vehicle, PAC DP-9 (25 µg/ml), or quercetin aglycone (10 µg/ml) for 6 h in complete DMEM media,
followed by cisplatin treatment alone or cisplatin + PAC DP-9/quercetin aglycone. Cells were incubated overnight for 12 h and analyzed via MTS for viability.
Experiments were performed in triplicate; data are expressed as mean ± SD in percent of cell viability of untreated cells (100%).

downregulation of both phosphorylated-EGFR and total
EGFR in SKOV-3 cells (Fig. 4A). As shown in Fig. 4B, EGFR
was expressed predominantly at the cell membrane in the
untreated controls, and exhibited nuclear translocation within
3 h of treatment with PAC DP-9 in a dose-dependent manner
such that lower concentrations (12.5-25 µg/ml) induced EGFR
peri-nuclear localization in SKOV-3 cells, and higher concentrations (50-200 µg/ml) of PAC DP-9 mediated EGFR nuclear
translocation.
Quercetin aglycone and PAC DP-9 downregulated prosurvival MAP kinase proteins in ovarian cancer cells. We
examined changes in MAP kinase signaling regulation exerted
by quercetin aglycone and PAC DP-9 in ovarian cancer cells.
Expression of MEK (Fig. 5A) and phospho-ERK1/2 (Fig. 5B)
was downregulated after 12 h of treatment with quercetin
aglycone or PAC DP-9, indicating inhibition of pro-survival
MAPK-ERK signal transduction by cranberry flavonoids.

Similarly, treatment with quercetin aglycone and PAC-9 led to
rapid, significant downregulation of phospho-p42/22 MAPK
and phospho-c-Raf in OVCAR-8 cells within 6 h (Fig. 6A),
demonstrating their inhibitory effect on the activated prosurvival MAPK pathway.
Quercetin aglycone and PAC DP-9 affected cell cycle
progression of ovarian cancer cells. Immunofluorescence
microscopy analysis of quercetin aglycone and PAC DP-9
treatment revealed downregulation of cyclin D1 and upregulation of p21 in SKOV-3 and OVCAR-8 cells (Fig. 5D and F).
Phospho-histone H3 (Fig. 5C) and DNA-dependent protein
kinase (DNA-PK, Fig. 5E), proteins often overexpressed in
ovarian cancer cells, were also downregulated in SKOV-3 and
OVCAR-8 cells upon treatment with cranberry flavonoids.
Based on immunoblot study, phospho-p53 and p21 expression
were first downregulated after 6 h of treatment with quercetin
aglycone in OVCAR-8 cells and then exhibited sustained
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Figure 4. Effects of quercetin aglycone and PAC DP-9 on expression, activation and localization of EGFR in SKOV-3 and OVCAR-8 cells. (A) Expression
of total and activated EGFR on cranberry flavonoid treated SKOV-3 and
OVCAR-8 cells. Cells were serum-deprived for 4 h and then treated with
5, 20 or 40 µg/ml quercetin aglycone or PAC DP-9 in serum-free DMEM
medium for 12 h. Actin was probed as internal loading control. (B) Effects
of PAC DP-9 on EGFR expression and localization in SKOV-3 cells. Cells
were treated with different concentrations (12.5-200 µg/ml) of PAC DP-9 for
3 h before fluorescent microscopic analysis. EGFR was visualized by Alexa
Fluor 594 secondary antibody (red), and nuclei were stained with DAPI.

upregulation (Fig. 6A). Three other cell cycle regulators,
p18, p27, and CDK2 were also upregulated within 6-24 h of
treatment with quercetin aglycone. Independent of p53 expression, SKOV-3 cells exhibited rapid upregulation of cell cycle
inhibitor p21 after 6 h of treatment of quercetin aglycone,
together with upregulation of p18, p27, and CDK2 within 24 h
of treatment. Similarly, PAC DP-9 induced upregulation of p21
in both SKOV-3 and OVCAR-8 cells within 6-24 h-treatment
regardless of p53 expression level. CDK2 expression was also
upregulated in SKOV-3 and OVCAR-8 cells after 24 h of
PAC DP-9 treatment.
Because immunofluorescence microscopy and western blot
analysis showed inhibition of SKOV-3 cellular EGFR expression by PAC DP-9 (Fig. 4), co-immunoprecipitation (Co-IP)
was utilized to examine potential protein-protein interactions
involved with EGFR and cell cycle regulatory factors, including
p18, p21, p27, CDK2, cyclin D1 and cyclin D3. While most
of the probed proteins did not show a positive signal, CDK2
signal was detected in both SKOV-3 and OVCAR-8 EGFR
Co-IP samples. As shown in Fig. 6B, CDK2 was recovered
in both positive controls and two Co-IP samples as well as
in the OVCAR-8 negative control, indicating a false-positive
signal in the OVCAR-8 Co-IP sample. The absence of CDK2
signal in SKOV-3 negative control confirmed direct interaction
between CDK2 and EGFR in SKOV-3 cells.
Both western blot and Co-IP studies indicate a direct
effect of cranberry flavonoids on ovarian cancer cell progression. Subpopulations of propidium iodide-stained SKOV-3
and OVCAR-8 ovarian cancer cells treated with cranberry
flavonoids were analyzed by flow cytometry. As illustrated
in Fig. 6C and D, quercetin aglycone or PAC DP-9 treatment

for 24 h in SKOV-3 cells led to G2/M-phase arrest dosedependently. The G2/M subpopulation increased from 10.81
to 16.52% for SKOV-3 cells treated with 50 µg/ml quercetin
aglycone and further increased to 32.35% after treatment
with 100 µg/ml quercetin aglycone. Similarly, 50 and 100 µg/
ml PAC DP-9 caused an increase in the SKOV-3 cell G2/M
subpopulation to 17.69 and 29.63%, respectively. After 48 h of
treatment in SKOV-3 cells, PAC DP-9 exhibited similar dosedependent G2/M-phase arrest, whereas 50 and 100 µg/ml
quercetin aglycone led to an increase in S subpopulation from
22.01 to 45.54 and 50.35%, respectively, with no significant
change in G2/M subpopulation. This suggests that quercetin
aglycone caused S/G2-phase arrest in SKOV-3 cells after 48 h
of treatment.
Quercetin aglycone treatment for 24 and 48 h in OVCAR-8
cells caused G1/S-phase arrest. At 50 µg/ml, quercetin aglycone
led to retention of 75.69 and 86.12% of cells in G0/G1 phase
after 24 and 48 h of treatment, respectively, and the subpopulation of S-phase cells decreased from 38.67 to 12.61% after
24 h and from 26.35 to 6.45% after 48 h (Fig. 6D). PAC DP-9
showed a similar effect in OVCAR-8 cells, thus confirming
that G1/S-phase arrest was caused by the two compounds in
OVCAR-8 ovarian cancer cells.
Discussion
Cranberry phenolic extracts have shown in vitro anticancer
and chemo-preventive properties in different cancer cell lines
(5-11). Research on individual phenolic compounds of cranberry has been limited by the difficulty of compound isolation
due to complex structural variations, including degree-of-
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Figure 5. Effect of quercetin aglycone and PAC DP-9 (12-h treatment) on cellular expression of MEK (A), phospho-ERK1/2 (B), phospho-histone H3 (C),
cyclin D1 (D), DNA-PK (E) and p21 (F) in SKOV-3 and OVCAR-8 cells. Cells were treated with either DMSO vehicle, PAC DP-9 (80 µg/ml), or quercetin
aglycone (80 µg/ml) for 12 h and stained for target proteins. MEK, cyclin D1 and p21 were probed by DyLight 488 secondary antibody (green); phosphoERK1/2, phospho-histone H3 and DNA-PK were probed by DyLight 594 secondary antibody (red).

polymerization, linkage type, position of the double linkage
between constituent units, and attachment with sugar moieties
(9,12). Serial application of Dionex UltiMate ® 3000 LC
system consisting of UltiMate 3000 RS Pump, UltiMate 3000
RS Autosampler, UltiMate 3000 RS Column Compartment,
and UltiMate 3000 RS Diode Array Detector coupled with
Applied Biosystems API 3000 triple quad LC-MS/MS mass
spectrometer has allowed the reproducible isolation and characterization of individual PACs with up to the 10th degree of

polymerization in >95% purity in our laboratories. So far, we
have successfully isolated 19 high-purity individual cranberry
flavonoids, characterized their structures by LC-APCI-MS,
and used them as primary materials to determine bioactivity.
SKOV-3 and OVCAR-8 ovarian cell lines, which possess
several key oncogenic hallmarks such as p53 mutation, EGFR
overexpression, and cisplatin resistance (16-18), were employed
as an in vitro cell culture model to determine the mechanism
of action of cranberry flavonoids. Individual PACs DP-2 to

1932

INTERNATIONAL JOURNAL OF ONCOLOGY 46: 1924-1934, 2015

Figure 6. Effect of PAC DP-9 and quercetin aglycone on cell cycle regulation in SKOV-3 and OVCAR-8 cells. (A) Western blot analysis of ERK-MAPK
signal components and cell cycle regulatory factors in SKOV-3 and OVCAR-8 cells after treatment with quercetin aglycone or PAC DP-9 (80 µg/ml) for
0-24 h. Tubulin was probed as an internal loading control; (B) EGFR co-immunoprecipitation on SKOV-3 and OVCAR-8 cell lysates. 1, SKOV-3 untreated
input control; 2, OVCAR-8 untreated input control; 3, SKOV-3 EGFR-co-immunoprecipitation; 4, OVCAR-8 EGFR-co-immunoprecipitation; 5, SKOV-3
IgG-co-immunoprecipitation control; 6, OVCAR-8 IgG-co-immunoprecipitation control. (C and D) Determination of cell cycle progression by FACS analysis
in SKOV-3 and OVCAR-8 cells treated with 50 or 100 µg/ml quercetin aglycone or PAC DP-9 for 24-48 h. Data are presented as relative fluorescence intensity
of G0/G1, S and G2/M phase subpopulations in 2-D charts (C) or tables (D).

DP-4 failed to show strong cytotoxicity against SKOV-3 cells,
and high molecular weight PAC polymers generally exhibited
stronger cytotoxicity similar to what we showed earlier (9).
Quercetin aglycone emerged as the most cytotoxic of the tested
cranberry flavonols. Shen et al showed that quercetin aglycone
exhibited significantly higher cytotoxicity against human
promyelocytic leukemia cells HL-60 compared to its rutinose
and rhamnose glycosides (19). Murota et al also reported that
quercetin aglycone was much more efficiently absorbed by
Caco-2 colorectal adenocarcinoma cells than its glycosides
(20). Both quercetin aglycone and PAC DP-9 induced ovarian
cancer cell death through apoptotic events, and subtoxic

concentrations of the two compounds significantly increased
the efficacy of cisplatin against ovarian cancer cells. Because
developed resistance to platinum-based drugs is one of the
major causes of mortality in ovarian cancer (2), the observation that cranberry flavonoids can sensitize drug-resistant
ovarian cancer cells to cisplatin provides an opportunity to
improve the efficacy of platinum chemotherapies and reduce
side effects associated with cisplatin.
EGFR, a receptor tyrosine kinase, is involved in many
signaling pathways that modulate cell survival, proliferation
and apoptosis. Aberrant activation of EGFR has been shown
to play a critical role in cancer cell survival and develop-
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ment (18,21). B-type PACs isolated from grape seeds have
been shown to target and downregulate EGFR expression in
human head and neck squamous cell carcinoma (HNSCC)
cells and inhibited their invasiveness (22). Our study showed
that treatment with A-type PAC DP-9 decreased expression
and activation and induced nuclear translocation of EGFR in
SKOV-3 cells dose-dependently. Association of EGFR with
DNA-PK, which is involved in DNA repair, has been previously reported (23,24), and its nuclear translocation has been
confirmed to modulate DNA repair caused by cisplatin or
radiation in mouse fibroblast cell lines (25). Although EGFR
nuclear translocation can be expected to activate DNA-PK as a
counter measure to DNA damage due to quercetin and PAC-9
treatment, immunofluorescence microscopy analysis revealed
downregulation of DNA-PK in ovarian cancer cells exposed
to quercetin aglycone or PAC DP-9. The DNA-PK-mediated
DNA repair that is induced by exposure to cisplatin in cancer
cells is believed to be an important factor in reducing the
efficacy of platinum-based chemotherapy (26,27). Therefore,
the inhibition of DNA-PK expression in quercetin aglycone or
PAC DP-9-treated ovarian cancer cells may partially account
for the increased efficacy of cisplatin in ovarian cancer cells
following quercetin aglycone or PAC DP-9 pre-treatment.
EGFR also regulates the extracellular signal-regulated
kinase ERK-MAPK pathway to maintain normal cell growth,
proliferation and differentiation (28). Aberrant activation of the
EGFR-Ras-Raf-MEK-ERK cascade is believed to contribute
to cancer development and progression (29). Both quercetin
aglycone and PAC DP-9 downregulated activated Raf, ERK1/2
and MEK in OVCAR-8 cells, suggesting the ERK-MAPK
pathway may be one of the anti-proliferative mechanisms. The
Raf-MEK-ERK pathway is also known to control cell cycle
progression through induction of key cell cycle regulatory
factors such as cyclins, cyclin-dependent kinases (CDKs), and
p21 (30). Phosphorylation of histone H3, which is believed to
play an important role in cell division and oncogene induction,
was shown to be stimulated by Ras-MAPK signaling pathway
(31,32). In our study, we report different levels of upregulation
of CDK inhibitors p18, p27, and most significantly, p21 after
treatment with quercetin aglycone or PAC DP-9, as well as
downregulation of cyclin D1 and phospho-histone H3, indicating their effects on cell cycle regulation. Expression of p21
can be induced by either p53-dependent or independent pathways (33,34). In SKOV-3 cells, where the p53 gene is mutated
and loses its expression, PAC DP-9 induced p21 upregulation
inversely correlated with the expression of ERK1/2, suggesting
that PAC DP-9 modulated a p53-independent ERK pathway
that mediates p21 regulation similar to a published mechanism
in rhabdosarcoma cells (34).
Upregulation of CDK inhibitors and downregulation of
cyclin D1 and phospho-histone H3 induced by the two cranberry flavonoids reflected the ability of quercetin aglycone and
PAC DP-9 to cause cell cycle arrest in SKOV-3 and OVCAR-8
cells. At concentrations lower than IC50, both quercetin aglycone and PAC DP-9 induced G1/S phase cell cycle arrest in
OVCAR-8 cells, consistent with the upregulation of cellular
p21 that has been shown to inhibit CDK regulation in G1/S
phase progression (35). On the other hand, SKOV-3 cells
showed cell cycle arrest at G2/M phase within 24 h of treatment with quercetin aglycone or PAC DP-9, similar as shown
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previously (10). Interestingly, CDK2, which is inhibited by
p21 and facilitates G1/S phase transition (35), was upregulated
after treatment with quercetin aglycone or PAC DP-9 in both
SKOV-3 and OVCAR-8 cells. We confirmed direct proteinprotein interaction between EGFR and CDK2 in SKOV-3 cells
through Co-IP, suggesting that CDK-2 overexpression could
be induced by nuclearly localized EGFR to facilitate DNA
repair and synthesis after exposure to quercetin aglycone or
PAC DP-9. These observations suggest that cell division of the
two ovarian cancer cell lines was regulated through different
mechanisms by cranberry flavonoids. Targeting cell cycle
checkpoints has been proposed as a promising approach to
cancer treatment (36).
In conclusion, our study suggests that certain cranberry
flavonols and PACs possess cytotoxic properties against
ovarian cancer cells. The integration of quercetin and/or
PAC DP-9 in ovarian cancer chemotherapy may provide
for improved outcomes. Quercetin aglycone and PAC DP-9
induced cellular apoptotic events including cell cycle arrest
and suppression of DNA repair pathways that highlight their
potential as dietarily available therapeutic agents.
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